logo-loader
viewOrgenesis

Orgenesis teams up with HemoGenyx in second collaboration to push cancer cell replacement product to clinical trials

In part two of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx Pharmaceuticals Plc (LON:HEMO), CEO Vered Caplan of Orgenesis and CEO Vladislav Sandler of HemoGenyx tell Proactive Investors the two biopharmas will work together yet again on HemoGenyx’s Human Postnatal Hemogenic Endothelial Cell (Hu-PHEC) technology.

Hu-PHEC is a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient.

As with the first agreement, Orgenesis will invest at least another $1million in HemoGenyx through a convertible loan, which can be converted into either HemoGenyx or Orgenesis stock.

Quick facts: Orgenesis

Price: 5.97 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $131.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Matador Mining raises A$8.7 million to fund major exploration program at...

Matador Mining Ltd's (ASX:MZZ) chairman Ian Murray speaks to Proactive soon after announcing they've raised A$8.7 million in a placement that was strongly supported by Australian and international institutional investors. He says they're now in a strong position to fund a major exploration...

3 minutes ago

2 min read